Marijuana Use and Organ Transplantation: a Review and Implications for Clinical Practice
Purpose of Review
Physicians of all disciplines must rapidly adjust their clinical practices following the expansion of marijuana legalization across the country. Organ transplantation teams are uniquely struggling in this gray zone with eight states having passed laws explicitly banning the denial of transplant listing based on a patient’s use of medical marijuana. In this review, we examine the clinical evidence of marijuana use in transplant patients to enable psychiatric providers to meaningfully contribute to the relevant medical and psychiatric aspects of this issue in a unique patient population.
There is no consensus among experts regarding marijuana use in transplantation patients. There are extant case reports of post-transplant complications attributed to marijuana use including membranous glomerulonephritis, ventricular tachycardia, and tacrolimus toxicity. However, recent studies suggest that the overall survival rates in kidney, liver, lung, and heart transplant patients using marijuana are equivalent to non-users.
Transplant teams should not de facto exclude marijuana users from transplant listing but instead holistically evaluate a patient’s candidacy, integrating meaningful medical, psychiatric, and social variables into the complex decision-making process. Psychiatric providers can play a key role in this process. Appropriate stewardship over donor organs, a limited and precious resource, will require a balance of high-clinical standards with inclusive efforts to treat as many patients as possible.
KeywordsMarijuana Cannabis Organ transplantation Transplantation Legalization Transplant psychiatry
The editors would like to thank Dr. Kamalika Roy for taking the time to review this manuscript.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.• Neyer J, Uberoi A, Hamilton M, Kobashigawa JA. Marijuana and listing for heart transplant: a survey of transplant providers. Circulation Heart failure. 2016;9(7):1-8. Online survey of transplant providers showing impact of marijuana use on listing for transplant. Google Scholar
- 3.Allen LA, Ambardekar AV. Hashing It Out Over Cannabis: Moving Toward a Standard Guideline on Substance Use for Cardiac Transplantation Eligibility That Includes Marijuana. Circ Heart Fail. 2016;9(7):1-3.Google Scholar
- 8.Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117–27.PubMedCrossRefGoogle Scholar
- 11.Lopez-Quintero C, de los Cobos JP, Hasin DS, Okuda M, Wang S, Grant BF, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the national epidemiologic survey on alcohol and related conditions (NESARC). Drug Alcohol Depend. 2011;115(1):120–30.PubMedCrossRefGoogle Scholar
- 17.Working to Reform Marijuana Laws. In: The National Organization for the Reform of Marijuana Laws.https://norml.org/legal/legalization. Accessed 14 May 2017
- 18.Working to Reform Marijuana Laws. In: The National Organization for the Reform of Marijuana Laws.https://norml.org/legal/medical-marijuana-2. Accessed 14 May 2017.
- 19.Greenberg RL. Medical marijuana post-McIntosh. City University of New York Law Review. 2016;20(1):12.Google Scholar
- 20.Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under US law. Epilepsy Behavior: E&B. 2017;70:288-91.Google Scholar
- 21.Drug Enforcement Administration DoJ. Applications to become registered under the controlled substances act to manufacture marijuana to supply researchers in the United States. Policy Statement Fed Regist. 2016;81(156):53846.Google Scholar
- 22.Leonard K (2017) DEA chief: 'Marijuana is not medicine'. In: Washington Examiner. https://www.washingtonexaminer.com/dea-chief-marijuana-is-not-medicine/article/2624211. Accessed 20 Sep 2017.
- 23.• Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292–7. Landmark review of marijuana’s impact on overall human behavior. PubMedCrossRefGoogle Scholar
- 24.ElSohly M. Potency monitoring program quarterly report no. 123—Reporting Period: 09: 16/2013–12/15/2013. Oxford, MS: University of Mississippi and National Institute for Drug Abuse; 2014.Google Scholar
- 27.Pierre JM. Risks of increasingly potent cannabis: the joint effects of potency and frequency. Curr Psychiatr Ther. 2017;16(2):14–20.Google Scholar
- 36.Winder GS, Stilger B, Ehrnstrom C, Hosanagar A. Veterans’ use of designer cathinones and cannabinoids. Federal Practioner. 2014;31(11):22–7.Google Scholar
- 46.Wall MM, Mauro C, Hasin DS, Keyes KM, Cerda M, Martins SS, et al. Prevalence of marijuana use does not differentially increase among youth after states pass medical marijuana laws: commentary on and reanalysis of US national survey on drug use in households data 2002–2011. Int J Drug Policy. 2016;29:9–13.PubMedPubMedCentralCrossRefGoogle Scholar
- 49.•• Mohite PN, Zeriouh M, Sáez DG, Popov A-F, Sabashnikov A, Zych B, et al. Influence of history of cannabis smoking in selected donors on the outcomes of lung transplantation. Eur J Cardiothorac Surg. 2017;51(1):142–7. Retrospective cohort study of liver transplant donors using marijuana. PubMedCrossRefGoogle Scholar
- 50.•• Xu DS, Hartman D, Ludrosky K, Campbell J, Starling RC, Taylor DO, et al. Impact of donor high-risk social behaviors on recipient survival in cardiac transplantation. Transplantation. 2010;89(7):873–8. Retrospective cohort study of heart transplant donors using marijuana among other high-risk social behaviors. PubMedCrossRefGoogle Scholar
- 51.Hauser N, Sahai T, Richards R, Roberts T. High on cannabis and calcineurin inhibitors: a word of warning in an era of legalized marijuana. Case Reports in Transplantation. 2016;2016:1-3.Google Scholar
- 54.Lázaro IJS, Bonet LA, Sancho-Tello MJ, Martínez-Dolz L. Ventricular tachycardia due to marijuana use in a heart transplant patient. Revista Española de Cardiología (English Edition). 2009;62(4):459–61.Google Scholar
- 55.Bohatyrewicz M, Urasinska E, Rozanski J, Ciechanowski K, editors. Membranous glomerulonephritis may be associated with heavy marijuana abuse. Transplantation Proceedings. Elsevier; 2007.Google Scholar
- 56.Catalano C, Seck S, Enia G. Severe hyponatraemia during sepsis and marijuana addiction. BMJ Case Rep. 2011;2011:1-2.Google Scholar
- 58.Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53(11):1566–70.Google Scholar
- 59.Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid Hyperemesis: A Case Series of 98 Patients. Mayo Clin Proc 2012;87(2):114–9.Google Scholar
- 60.Hézode C, Roudot‐Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42(1):63–71.Google Scholar
- 63.Levenson JL. The American psychiatric publishing textbook of psychosomatic medicine: psychiatric care of the medically ill. Arlington: American Psychiatric Pub; 2011.Google Scholar
- 68.Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. J Am Soc Anesthesiologists. 2007;107(5):785–96.Google Scholar
- 81.Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian G, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med. 2011;50(10):1368–81.PubMedPubMedCentralCrossRefGoogle Scholar
- 84.Brunet L, Moodie EE, Rollet K, et al. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013;57(5):663–70.Google Scholar
- 92.Meng H, Hanlon JG, Katznelson R, Ghanekar A, McGilvray I, Clarke H. The prescription of medical cannabis by a transitional pain service to wean a patient with complex pain from opioid use following liver transplantation: a case report. Can J Anesth/Journal canadien d'anesthésie. 2016;63(3):307–10.PubMedCrossRefGoogle Scholar
- 94.Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. The Cochrane Library. 2013(4):1-45.Google Scholar
- 98.Network OPaT. OPTN: organ procurement and transplantation network—OPTN. 2017. https://optn.transplant.hrsa.gov/. Accessed 11 June 2017.